POINT: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: The problem of understaging

被引:55
作者
Stiles, Brendon M. [1 ]
Servais, Elliot L. [1 ]
Lee, Paul C. [1 ]
Port, Jeffrey L. [1 ]
Paul, Subroto [1 ]
Altorki, Nasser K. [1 ]
机构
[1] Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Div Thorac Surg, New York, NY 10021 USA
关键词
PROSPECTIVE TRIAL; RESECTION; MEDIASTINOSCOPY; LESS; RECURRENCE; LOBECTOMY; DIAMETER; SURVIVAL; INVASION; CM;
D O I
10.1016/j.jtcvs.2008.09.045
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: There is an increase in interest in limited resection for clinical stage IA non-small cell lung cancer. The purpose of this study was to evaluate the accuracy of the diagnosis of clinical stage IA non-small cell lung cancer when determined by both computed tomography and positron emission tomography scans and to determine factors associated with understaging. Methods: A retrospective review of a prospectively maintained database of patients with non-small cell lung cancer was performed. Patients with clinical stage IA cancer determined by preoperative computed tomography and positron emission tomography scan were reviewed. The influence of the following factors was analyzed with regard to accuracy of clinical staging: tumor size, location, histology, and positron emission tomography positivity. Results: Of the 266 patients identified, cancer was correctly staged in 65%. Final pathologic stages also included IB (15%), IIA (2.6%), IIB (4.1%), IIIA (4.9%), IIIB (7.5%), and IV (.08%). Positive lymph nodes were found in 11.7% of patients. Pathologic T classification changed in 28.2% of patients. Cancer in patients with clinical tumor size greater than 2 cm (n = 68) was significantly more likely to be understaged than in patients with tumors 2 cm or less (49% vs 29%, P = .003). Cancer in patients with a positron emission tomography-positive (positron emission tomography+VE) primary evaluation (n = 218) was also more likely to be understaged (39% vs 15%, P = .001). Of patients with positron emission tomography+VE tumors greater than 2 cm, cancer was clinically understaged in 55%, compared with 32% for positron emission tomography+VE tumors 2 cm or less, and only 17% for positron emission tomography negative (-VE) tumors less than 2 cm. Conclusion: Clinical stage IA lung cancer is frequently understaged in patients. Size greater than 2 cm and positron emission tomography positivity are risk factors for understaging. Limited resection should be undertaken with caution in such patients.
引用
收藏
页码:13 / 19
页数:7
相关论文
共 34 条
[1]   Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration [J].
Aquino, SL ;
Asmuth, JC ;
Alpert, NM ;
Halpern, EF ;
Fischman, AJ .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2003, 27 (04) :479-484
[2]   A new method of segmental resection for primary lung cancer: intermediate results [J].
Bando, T ;
Yamagihara, K ;
Ohtake, Y ;
Miyahara, R ;
Tanaka, F ;
Hasegawa, S ;
Inui, K ;
Wada, H .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2002, 21 (05) :894-899
[3]   The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival [J].
Cerfolio, RJ ;
Bryant, AS ;
Ohja, B ;
Bartolucci, AA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 130 (01) :151-159
[4]   Improving the inaccuracies of clinical staging of patients with NSCLC: A prospective trial [J].
Cerfolio, RJ ;
Bryant, AS ;
Ojha, B ;
Eloubeidi, M .
ANNALS OF THORACIC SURGERY, 2005, 80 (04) :1207-1214
[5]   Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial [J].
D'Cunha, J ;
Herndon, JE ;
Herzan, DL ;
Patterson, GA ;
Kohman, LJ ;
Harpole, DH ;
Kernstine, KH ;
Kern, JA ;
Green, MR ;
Maddaus, MA ;
Kratzke, RA .
LUNG CANCER, 2005, 48 (02) :241-246
[6]   Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: A 13-year analysis [J].
El-Sherif, Amgad ;
Gooding, William E. ;
Santos, Ricardo ;
Pettiford, Brian ;
Ferson, Peter F. ;
Fernando, Hiran C. ;
Urda, Susan J. ;
Luketich, James D. ;
Landreneau, Rodney J. .
ANNALS OF THORACIC SURGERY, 2006, 82 (02) :408-416
[7]  
FERNANDO HC, 1990, CANCER-AM CANCER SOC, V65, P2503, DOI 10.1002/1097-0142(19900601)65:11<2503::AID-CNCR2820651119>3.0.CO
[8]  
2-W
[9]   Tumor size is a determinant of stage distribution in T1 non-small cell lung cancer [J].
Flieder, DB ;
Port, JL ;
Korst, RJ ;
Christos, PJ ;
Levin, MA ;
Becker, DE ;
Altorki, NK .
CHEST, 2005, 128 (04) :2304-2308
[10]   A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer [J].
Gonzalez-Stawinski, GV ;
Lemaire, A ;
Merchant, F ;
O'Halloran, E ;
Coleman, RE ;
Harpole, DH ;
D'Amico, TA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 126 (06) :1900-1905